Achieve Life Sciences (ACHV) EBITDA (2010 - 2018)

Achieve Life Sciences (ACHV) has 7 years of EBITDA data on file, last reported at $43.5 million in Q4 2018.

• Quarterly EBITDA rose 1344.59% year-over-year to $43.5 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $38.7 million (up 12.96% YoY) and the FY2019 annual result came in at -$16.2 million, down 147.1% from the prior year.
• EBITDA advanced to $43.5 million in Q4 2018, from -$1.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $45.7 million in Q1 2017 to a low of -$7.8 million in Q3 2017.
• A 4-year average of $6.4 million and a median of -$1.2 million in 2015 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2017 — EBITDA tumbled 2444.26% — and 2018, when it surged 1344.59%.
• Tracing ACHV's EBITDA over 4 years: stood at -$1.2 million in 2015, then surged by 53.75% to -$567000.0 in 2016, then slumped by 516.23% to -$3.5 million in 2017, then surged by 1344.59% to $43.5 million in 2018.
• The last three EBITDA figures came in at $43.5 million (Q4 2018), -$1.8 million (Q3 2018), and -$1.4 million (Q2 2018), per Business Quant data.